News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA OKs Stronger Warning for Takeda Pharmaceutical Co. Ltd. (TKDG.DE)'s Diabetes Drug Pioglitazone



8/8/2011 8:12:09 AM

The FDA has approve updated drug labels for pioglitazone-containing medicines to include a safety warning that the use of pioglitazone for more than 1 year may be associated with an increased risk for bladder cancer. According to the new drug label, health care professionals should: Not use pioglitazone in patients with active bladder cancer. Use pioglitazone with caution in patients with a prior history of bladder cancer. In addition, patients are encouraged to contact their health care professional if experiencing any sign of blood in the urine or symptoms such as new or worsening urinary urgency or pain on urination since starting pioglitazone (Takeda). These symptoms may be related to bladder cancer.

Read at News Release
Read at News Release


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES